Results 61 to 70 of about 2,524 (195)

Postpandemic Trends in Pediatric Respiratory Virus Hospitalizations: A Multicenter Study, 2019–2025

Influenza and Other Respiratory Viruses, Volume 20, Issue 10, October 2026.
ABSTRACT Background The COVID‐19 pandemic profoundly altered the circulation of respiratory viruses in children, changing the epidemiology of acute lower respiratory tract infections. In the postpandemic period, respiratory pathogens showed marked temporal variability. The 2024–2025 season was the first respiratory syncytial virus (RSV) season in Italy
Federica Attaianese, Silvia Campani, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli, Enrico Felici, Anna Frusciante, Maria Antonia Galeone, Silvia Garazzino, Antonietta Giannattasio, Eloisa Gitto, Antonio Guerriero, Fiorentina Guida, Giovanna Iudica, Marcello Lanari, Claudia Mandato, Alice Manzini, Gaia Martelli, Gregorio Paolo Milani, Maria Moriondo, Lucia Dora Notarangelo, Felice Nunziata, Roberta Pellegrino, Diego Peroni, Emanuela Piccotti, Eduardo Ponticiello, Silvia Ricci, Immacolata Rulli, Fabio Savoia, Erika Silvestro, Antonella Sisto, Federica Soro, Stefania Tonetto, Alessandro Zago, Carlo Dani, Chiara Azzari, Giuseppe Indolfi   +43 more
wiley   +1 more source

RSV Molecular Epidemiology Pre‐ and Post‐COVID‐19 Pandemic Periods in Seattle, Washington, USA

Influenza and Other Respiratory Viruses, Volume 20, Issue 10, October 2026.
ABSTRACT Background Globally, RSV declined to historically low levels following stay‐at‐home orders in 2020 and re‐emerged as restrictions lifted, with large inter‐seasonal outbreaks and other shifts in epidemiology. The effect of the pandemic restrictions on genomic diversity has not been well studied.
Pavitra Roychoudhury, Julia C. Bennett, Anna Elias‐Warren, Erica Wetzler, Lea M. Starita, Jeremy Stone, Ben Capodanno, Robin Prentice, Peter D. Han, Sally B. Grindstaff, David Reinhart, Jennifer K. Logue, Caitlin R. Wolf, Michael Boeckh, Christina M. Lockwood, Amanda C. Perofsky, Cécile Viboud, Jay Shendure, Trevor Bedford, Marco Carone, Janet A. Englund, Helen Y. Chu   +21 more
wiley   +1 more source

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis

Frontiers in Immunology
BackgroundRespiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society.
Xiaopeng Wang, Xiaopeng Wang, Xiaopeng Wang, Li Kong, Li Kong, Li Kong, Xueou Liu, Panpan Wu, Panpan Wu, Panpan Wu, Lulu Zhang, Lulu Zhang, Lulu Zhang, Fangrui Ding, Fangrui Ding, Fangrui Ding   +15 more
doaj   +1 more source

Sociodemographic Characteristics of Infants Receiving Nirsevimab

JAMA Network Open
This cohort study investigates inequalities by sociodemographic group in the receipt of nirsevimab immunization by infants in France from 2023 to 2024.
Boutin, Salomé, Bertrand, Marion, Cohen, Jérémie F., Zureik, Mahmoud, Chalumeau, Martin, Jabagi, Marie-Joëlle   +5 more
openaire   +2 more sources

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study

Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants. In 2024, the monoclonal antibody nirsevimab became available in Italy for all newborns during their first RSV season. Aims: The
Bonci, Enea, Petrarca, Laura, Spatuzzo, Mattia, Nenna, Raffaella, La Regina, Domenico Paolo, Antonelli, Guido, Midulla, Fabio, Pierangeli, Alessandra, Conti, Maria Giulia, Mancino, Enrica   +9 more
core   +1 more source

Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center

Molecular and Cellular Pediatrics
Background Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data
Moritz Bauer, Anke Wendt, Marcus A. Mall, Horst von Bernuth, Stephanie Thee   +4 more
doaj   +1 more source

Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)

Viruses
Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the
Paolo Manzoni, Matteo Riccò, Chryssoula Tzialla, Graziano Barera, Paolo Del Barba, Simona De Franco, Guido Pellegrini, Enrico Crapanzano, Giangiacomo Nicolini, Andrea Alba, Stefano Fiocchi, Mauro Vivalda, Giulia Natta, Alessandra Casati, Mariano Manzionna, Simone Rugolotto, Laura Saggioro, Simona Pesce, Maria Scavone, Antonietta Distilo, Vincenza Roseto, Antonino Di Toro, Luca Pierri, Gianfranco Scarpelli, Elvira Bonanno, Lidia Decembrino, Enrico Felici, Camilla Selvatico, Valentina Saracco, Francesco Morrone, Claudio Costantino, Cecilia Nobili, Mario Giuffrè   +32 more
doaj   +1 more source

RSV‐Pre‐F Vaccination During Pregnancy and Neonatal Outcomes—A Systematic Review and Meta‐Analysis

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Objectives Respiratory syncytial virus (RSV) is a major cause of infant morbidity and mortality worldwide. Recent preventive strategies include maternal vaccination and monoclonal antibodies. However, maternal RSV vaccination has raised safety concerns due to possible associations with preterm birth.
Niko Leskinen, Marjut Haapanen, Ilari Kuitunen   +2 more
wiley   +1 more source

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea

Human Vaccines & Immunotherapeutics
The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared ...
Hyun Jin Han, Semin Jang, Ryu Dahye, Haeseon Lee, Jiyeon Lee, Eun Jin Bae, Samira Soudani, Hae Sun Suh   +7 more
doaj   +1 more source

Reluctance of parents to immunize their children with nirsevimab

Anales de Pediatría (English Edition)
2025
Piñeiro Pérez, Roi, Galán Arévalo, Sonsoles, Risso, Milagros, Hidalgo Montes, Inmaculada, López Escobar, Alejandro   +4 more
openaire   +3 more sources